
Envista Holdings Corp
NVSTNYSEHealthcareMedical - Instruments & Supplies
Regular session
$27.33
+$0.13 · +0.48%
NVST company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
80
Undervalued
Momentum
55
Neutral
Sentiment
70
Bullish
Risk resilience
69
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEnvista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Paul A. Keel
- Listed since
- Sep 18, 2019
- Employees
- 12,000
Market position
Day range
Current $27.33
52-week range
Current $27.33
- Open
- $27.305
- Previous close
- $27.20
- Volume
- 387.43K
- 0.13× average
- Average volume
- 3.08M
- Average daily volume
- Market cap
- 4.45B USD
- Beta
- 0.86
- Market reference 1
- 50-day average
- $26.8086
- +1.94% above average
- 200-day average
- $24.9217
- +9.66% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 4.03B USD
- P/E (TTM)
- 46.32×
- P/B (TTM)
- 1,438,327.54×
- P/S (TTM)
- 1.56×
- EV / EBITDA
- 12.23×
- Earnings yield
- 1.29%
- Free cash flow yield
- 6.32%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 55.50%
- Operating margin
- 9.92%
- Net margin
- 3.33%
- Return on equity
- 1.51%
- Return on assets
- 0.83%
- Return on invested capital
- 1.23%
Financial health
- Debt / equity
- 0.52×
- Current ratio
- 2.38×
- Altman Z-score
- 1,714,045.15
- Piotroski F-score
- 8 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.72B USD | 2.51B USD | 2.57B USD | 2.57B USD | 2.51B USD |
| Cost of goods sold | 1.22B USD | 1.12B USD | 1.12B USD | 1.08B USD | 1.05B USD |
| Gross profit | 1.5B USD | 1.39B USD | 1.45B USD | 1.49B USD | 1.46B USD |
| Research and development | 114M USD | 99.1M USD | 93.8M USD | 100.1M USD | 100.5M USD |
| Selling, general, and administrative | 1.16B USD | 1.14B USD | 1.03B USD | 1.03B USD | 989.5M USD |
| Operating expenses | 1.27B USD | 2.43B USD | 1.42B USD | 1.17B USD | 1.16B USD |
| Interest expense | 36.6M USD | 46.4M USD | 63.4M USD | 38.4M USD | 54.1M USD |
| Depreciation and amortization | 116M USD | 123.1M USD | 135.6M USD | 137.8M USD | 123.6M USD |
| Operating income | 225.7M USD | −1.04B USD | 31.5M USD | 319.2M USD | 306.2M USD |
| Net income | 47M USD | −1.12B USD | −100.2M USD | 243.1M USD | 340.5M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- +4.93%
- 11 comparable reports
- Latest EPS result
- 0.41
- Estimate 0.34 · Beat by 22.28%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$29.14
6.62% upsidePrice history unavailable
High $34.00Average $29.14Low $23.00NVST peers
Continue in GoAI
Research NVSTresearch.disclaimer





